The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease

Journal of Clinical Investigation

Volumn 120, Issue 1, 2010, Pages 343-356

  Na, Il Kang ^a,b   Lu, Sydney X ^a   Yim, Nury L ^a   Goldberg, Gabrielle L ^a   Tsai, Jennifer ^a   Rao, Uttam ^a   Smith, Odette M ^a   King, Christopher G ^a   Suh, David ^a   Hirschhorn Cymerman, Daniel ^a   Palomba, Lia ^a   Penack, Olaf ^a,b   Holland, Amanda M ^a,c   Jenq, Robert R ^a   Ghosh, Arnab ^a   Tran, Hien ^a   Merghoub, Taha ^a   Liu, Chen ^d   Sempowski, Gregory D ^e   Ventevogel, Melissa ^e   Beauchemin, Nicole ^f   Van Den Brink, Marcel R M ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Weill Cornell Graduate School of Biomedical Sciences   (United States)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTEGRIN; BETA7 INTEGRIN; CARCINOEMBRYONIC ANTIGEN RELATED CELL ADHESION MOLECULE 1; CASPASE 8; CD134 ANTIGEN; CHEMOKINE RECEPTOR CCR2; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; DEATH RECEPTOR 5; FAS LIGAND; INHIBITOR PROTEIN; L SELECTIN; P SELECTIN GLYCOPROTEIN LIGAND 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; FLICE INHIBITORY PROTEIN; TNFRSF4 PROTEIN, MOUSE; TNFSF10 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW TRANSPLANTATION; CELL FUNCTION; CONDITIONING; CONTROLLED STUDY; CYTOARCHITECTURE; CYTOLYSIS; DONOR; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; LYMPHOCYTE FUNCTION; MOUSE; NONHUMAN; PRE T LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN INTERACTION; RADIATION; STROMA CELL; T LYMPHOCYTE; THYMUS GRAFT; UPREGULATION; ALLOTRANSPLANTATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL MOTION; CYTOLOGY; DRUG POTENTIATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PHYSIOLOGY; THYMUS;

ANIMALS; BONE MARROW TRANSPLANTATION; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CELL MOVEMENT; FAS LIGAND PROTEIN; GRAFT VS HOST DISEASE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, OX40; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; STROMAL CELLS; T-LYMPHOCYTES; THYMUS GLAND; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSPLANTATION, HOMOLOGOUS;

EID: 74949142625     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI39395     Document Type: Article

References (62)

1. Ochs L, et al. Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients. Blood. 1995;86(10):3979-3986.
2. Socie G, et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone marrow Transplant Registry. N Engl J Med. 1999;341(1):14-21.
3. Maraninchi D, et al. Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet. 1987;2(8552):175-178.
4. Roux E, et al. Recovery of immune reactivity after T-cell-depleted bone marrow transplantation depends on thymic activity. Blood. 2000;96(6):2299-2303.
5. Dumont-Girard F, et al. Reconstitution of the T-cell compartment after bone marrow transplantation: restoration of the repertoire by thymic emigrants. Blood. 1998;92(11):4464-4471.
6. Mackall CL, Gress RE. Pathways of T-cell regeneration in mice and humans: implications for bone marrow transplantation and immunotherapy. Immunol Rev. 1997;157:61-72.
7. Patel DD, et al. Thymic function after hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. N Engl J Med. 2000;342(18):1325-1332.
8. Hakim FT, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 1997;90(9):3789-3798.
9. Mackall CL, et al. Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med. 1995;332(3):143-149.
10. Small TN, et al. Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999;93(2):467-480.
11. Douek DC, et al. Assessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet. 2000;355(9218):1875-1881.
12. Weinberg K, Annett G, Kashyap A, Lenarsky C, Forman SJ, Parkman R. The effect of thymic function on immunocompetence following bone marrow transplantation. Biol Blood Marrow Transplant. 1995;1(1):18-23.
13. Lapp WS, Ghayur T, Mendes M, Seddik M, Seemayer TA. The functional and histological basis for graftversus-host-induced immunosuppression. Immunol Rev. 1985;88:107-133.
14. Seemayer TA, Lapp WS, Bolande RP. Thymic involution in murine graft-versus-host reaction. Epithelial injury mimicking human thymic dysplasia. Am J Pathol. 1977;88(1):119-134.
15. Ghayur T, Seemayer TA, Xenocostas A, Lapp WS. Complete sequential regeneration of graft-vs.-hostinduced severely dysplastic thymuses. Implications for the pathogenesis of chronic graft-vs.-host disease. Am J Pathol. 1988;133(1):39-46.
16. Seddik M, Seemayer TA, Lapp WS. T cell functional defect associated with thymid epithelial cell injury induced by a graft-versus-host reaction. Transplantation. 1980;29(1):61-66.
17. van Ewijk W, et al. Thymic microenvironments, 3-D versus 2-D? Semin Immunol. 1999;11(1):57-64.
18. Hollander GA, Widmer B, Burakoff SJ. Loss of normal thymic repertoire selection and persistence of autoreactive T cells in graft vs host disease. J Immunol. 1994;152(4):1609-1617.
19. van den Brink MR, Moore E, Ferrara JL, Burakoff SJ. Graft-versus-host- disease-associated thymic damage results in the appearance of T cell clones with anti-host reactivity. Transplantation. 2000;69(3):446-449.
20. Krenger W, Rossi S, Hollander GA. Apoptosis of thymocytes during acute graft-versus-host disease is independent of glucocorticoids. Transplantation. 2000;69(10):2190-2193.
21. Krenger W, Rossi S, Piali L, Hollander GA. Thymic atrophy in murine acute graft-versus-host disease is effected by impaired cell cycle progression of host pro-T and pre-T cells. Blood. 2000;96(1):347-354.
22. Hauri-Hohl MM, et al. Donor T-cell alloreactivity against host thymic epithelium limits T-cell development after bone marrow transplantation. Blood. 2007;109(9):4080-4088.
23. Kelly RM, et al. Keratinocyte growth factor and androgen blockade work in concert to protect against conditioning regimen-induced thymic epithelial damage and enhance T-cell reconstitution after murine bone marrow transplantation. Blood. 2008;111(12):5734-5744.
24. Panoskaltsis-Mortari A, et al. Keratinocyte growth factor facilitates alloengraftment and ameliorates graft-versus-host disease in mice by a mechanism independent of repair of conditioning-induced tissue injury. Blood. 2000;96(13):4350-4356.
25. Cooke KR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996;88(8):3230-3239.
26. Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389-399.
27. Taylor PA, Lees CJ, Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood. 2002;99(10):3493-3499.
28. Schmaltz C, et al. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood. 2001;97(9):2886-2895.
29. Schmaltz C, et al. T cells require TRAIL for optimal graft-versus-tumor activity. Nat Med. 2002;8(12):1433-1437.
30. Dutt S, et al. L-selectin and beta7 integrin on donor CD4 T cells are required for the early migration to host mesenteric lymph nodes and acute colitis of graft-versus-host disease. Blood. 2005;106(12):4009-4015.
31. Perry SS, et al. L-selectin defines a bone marrow analog to the thymic early T-lineage progenitor. Blood. 2004;103(8):2990-2996.
32. Perry SS, Welner RS, Kouro T, Kincade PW, Sun XH. Primitive lymphoid progenitors in bone marrow with T lineage reconstituting potential. J Immunol. 2006;177(5):2880-2887.
33. Rossi FM, et al. Recruitment of adult thymic progenitors is regulated by P-selectin and its ligand PSGL-1. Nat Immunol. 2005;6(6):626-634.
34. Uehara S, Grinberg A, Farber JM, Love PE. A role for CCR9 in T lymphocyte development and migration. J Immunol. 2002;168(6):2811-2819.
35. Duffner U, et al. Role of CXCR3-induced donor T-cell migration in acute GVHD. Exp Hematol. 2003;31(10):897-902.
36. El-Asady R, et al. TGF-{beta}-dependent CD103 expression by CD8(+) T cells promotes selective destruction of the host intestinal epithelium during graft-versus-host disease. J Exp Med. 2005;201(10):1647-1657.
37. Petrovic A, et al. LPAM (alpha 4 beta 7 integrin) is an important homing integrin on alloreactive T cells in the development of intestinal graft-versus-host disease. Blood. 2004;103(4):1542-1547.
38. Waldman E, et al. Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine. Blood. 2006;107(4):1703-1711.
39. Shlomchik WD. Graft-versus-host disease. Nat Rev Immunol. 2007;7(5):340-352.
40. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol. 2006;6(3):196-204.
41. Beilhack A, et al. In vivo analyses of early events in acute graft-versus-host disease reveal sequential infiltration of T-cell subsets. Blood. 2005;106(3):1113-1122.
42. Longo DL, Davis ML. Early appearance of donortype antigen-presenting cells in the thymuses of 1200 R radiation-induced bone marrow chimeras correlates with self-recognition of donor I region gene products. J Immunol. 1983;130(6):2525-2527.
43. Uchimura E, Watanabe N, Niwa O, Muto M, Kobayashi Y. Transient infiltration of neutrophils into the thymus in association with apoptosis induced by whole-body X-irradiation. J Leukoc Biol. 2000;67(6):780-784.
44. Hubbard VM, et al. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation. Blood. 2005;106(9):3285-3292.
45. Muriglan SJ, et al. GITR activation induces an opposite effect on alloreactive CD4(+) and CD8(+) T cells in graft-versus-host disease. J Exp Med. 2004;200(2):149-157.
46. Baker MB, Riley RL, Podack ER, Levy RB. Graft-versus-host-disease- associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cellmediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci U S A. 1997;94(4):1366-1371.
47. van den Brink MR, Burakoff SJ. Cytolytic pathways in haematopoietic stem-cell transplantation. Nat Rev Immunol. 2002;2(4):273-281.
48. Tsao GJ, Allen JA, Logronio KA, Lazzeroni LC, Shizuru JA. Purified hematopoietic stem cell allografts reconstitute immunity superior to bone marrow. Proc Natl Acad Sci U S A. 2009;106(9):3288-3293.
49. Clave E, et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood. 2009;113(25):6477-6484.
50. Borsotti C, et al. Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity. Blood. 2007;110(2):783-786.
51. Terwey TH, et al. CCR2 is required for CD8-induced graft-versus-host disease. Blood. 2005;106(9):3322-3330.
52. Rossi S, et al. Keratinocyte growth factor preserves normal thymopoiesis and thymic microenvironment during experimental graft-versus-host disease. Blood. 2002;100(2):682-691.
53. Schmaltz C, et al. Donor T cell-derived TNF is required for graft-versus-host disease and graft-versus-tumor activity after bone marrow transplantation. Blood. 2003;101(6):2440-2445.
54. van Den Brink MR, et al. Fas-deficient lpr mice are more susceptible to graft-versus-host disease. J Immunol. 2000;164(1):469-480.
55. van den Brink MR, et al. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease. Transplantation. 2000;70(1):184-191.
56. Blau DM, et al. Targeted disruption of the Ceacam1 (MHVR) gene leads to reduced susceptibility of mice to mouse hepatitis virus infection. J Virol. 2001;75(17):8173-8186.
57. -/- mice are completely resistant to infection by murine coronavirus mouse hepatitis virus A59. J Virol. 2004;78(18):10156-10165.
58. Yang J, et al. Targeted gene disruption demonstrates that P-selectin glycoprotein ligand 1 (PSGL-1) is required for P-selectin-mediated but not E-selectin-mediated neutrophil rolling and migration. J Exp Med. 1999;190(12):1769-1782.
59. Alpdogan O, et al. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J Clin Invest. 2003;112(7):1095-1107.
60. Alpdogan SO, et al. Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation. Blood. 2008;112(12):4755-4764.
61. Takeda K, et al. Induction of tumor-specific T cell immunity by anti-DR5 antibody therapy. J Exp Med. 2004;199(4):437-448.
62. Gray DH, Chidgey AP, Boyd RL. Analysis of thymic stromal cell populations using flow cytometry. J Immunol Methods. 2002;260(1-2):15-28.